BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

  News

DeepMind & MIT Alumni Raise $13.5M to Build «Generative Knowledge Discovery» AI

by Anastasiia Rohozianska   •   March 10, 2026

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Biotech Ventures   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

Palo Alto- and Cambridge-based Unreasonable Labs has emerged from stealth with $13.5 million in funding to develop an AI platform designed for “generative knowledge discovery”. It is designed to go beyond current AI tools that mainly search or summarize existing knowledge, allowing the system to connect ideas across fields, propose new scientific hypotheses, test them in simulations, and outline experiments.

The funding round was led by Playground Global, with participation from AIX Ventures, E14 Fund, and MS&AD Ventures. The company was founded by Yuan Cao, formerly a senior staff research scientist at Google DeepMind, and Prof. Markus Buehler, an engineering professor at MIT known for work in computational materials science and AI-driven discovery.

In addition to the founders, the company lists several advisors including physicist Nobel Prize in Physics winner Konstantin Novoselov, MIT biotechnology researcher Robert Langer, and Hugging Face co-founder Thomas Wolf.

Unreasonable’s system combines large language models with neurosymbolic mathematical abstractions designed to represent physical and chemical principles. Instead of relying only on patterns learned during training, the company is building a general framework designed to help AI reason across different scientific fields.

This structure converts scattered research data into an organized network of entities and relationships, allowing the system to analyze information more systematically and trace how conclusions are reached. Scientists can also modify the reasoning rules, making the system’s logic easier to inspect and adjust. This allows the AI to combine ideas in creative ways, a uniquely human capability important for generating original scientific hypotheses and discoveries.

Within this framework, the system is designed to support several stages of scientific research. It can combine information from multiple disciplines into a unified knowledge model, identify connections between distant concepts to suggest new hypotheses, test ideas using physics-based simulations before experiments are conducted, and translate promising results into experimental protocols while incorporating feedback from laboratory data.

According to the company, the approach is designed to address a growing bottleneck in scientific research: the rapid expansion of technical information across disciplines. 

The platform is also designed to interact with simulation environments and experimental hardware, creating a feedback loop in which hypotheses generated computationally can be evaluated through modeling and then refined based on experimental data.

Unreasonable reports that it has begun pilot collaborations with industrial partners in areas including energy technologies, materials science, and pharmaceuticals. The company plans to use the new funding to expand engineering and machine learning teams focused on simulation, scientific computing, and AI model development.

Cover image credit Unreasonable Labs

Topic: Biotech Ventures

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.